世界の創傷ケア用生物製剤市場は、2022年の18億ドルから、2027年までに24億ドルに達し、CAGRは5.4％になると予測されます。市場の成長を促す要因は、火傷の発生率の増加と創傷治療用生物製剤の技術革新です。
COVID-19パンデミックの出現によって、世界中で医療の提供が変わりました。COVID-19患者の入院率の上昇によって圧力が高まったことから、COVID-19患者を治療するために多くの病院や部門の再プロファイリングが必要になりました。その結果、利用可能な限られた能力と資源（病床や医療従事者など）をCOVID-19患者ケアに予約する、または振り向けるために、多くの待機的手術がキャンセルや延期を余儀なくされました。
Advances in Wound Careに発表された研究によると、2020年6月までに、COVID-19サービス業務中にPPEキットを着用しているヘルスケアサービスプロバイダーの80％が、デバイス関連の圧力による怪我、皮膚裂傷など、複数の種類の皮膚損傷を負っていたと報告されています。これらの傷害によって、極端な場合や慢性創傷では、皮膚弁が部分的または完全に失われる可能性があります。このような傷は、主に鼻梁、頬、耳、額、脇の下、鼠径部、四肢などの領域で発生します。このような皮膚損傷の全症例のうち、68.2％がデバイス関連の圧力による怪我であり、26.1％が湿潤による皮膚損傷であり、5.7％が部分的または全層の皮膚の裂傷でしたこのような怪我を治療するために、医師と看護師（グレード2および3のPPEキットを使用）は、創傷治療の生物学製剤を使用して、より迅速な創傷治癒を促進しました。COVID-19パンデミックの間、および予測期間中は、世界中のそのようなケースが創傷ケア用生物製剤市場の成長を促進すると予想されます。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 WOUND CARE BIOLOGICS MARKET
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 31)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 WOUND CARE BIOLOGICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 3: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 41)
FIGURE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 10 WOUND CARE BIOLOGICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 11 WOUND CARE BIOLOGICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 44)
4.1 WOUND CARE BIOLOGICS MARKET OVERVIEW
FIGURE 12 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET FOR WOUND CARE BIOLOGICS
4.2 WOUND CARE BIOLOGICS MARKET SHARE, BY PRODUCT, 2022 VS. 2027
FIGURE 13 BIOLOGICAL SKIN SUBSTITUTES WILL CONTINUE TO DOMINATE MARKET IN 2027
4.3 WOUND CARE BIOLOGICS MARKET SHARE, BY WOUND TYPE, 2022 VS. 2027
FIGURE 14 ULCERS SEGMENT DOMINATES MARKET
4.4 WOUND CARE BIOLOGICS MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 15 HOSPITALS ARE LARGEST END USERS OF WOUND CARE BIOLOGICS
4.5 WOUND CARE BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN WOUND CARE BIOLOGICS MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of diseases & conditions affecting wound healing capabilities
5.2.1.1.1 Growing geriatric population
5.2.1.1.2 Increasing prevalence of diabetes and target conditions
FIGURE 18 PREVALENCE OF DIABETES IN ADULTS (20-79 YEARS), BY REGION, 2021 VS. 2045 (MILLION CASES)
TABLE 1 TOTAL HEALTH EXPENDITURE (USD) DUE TO DIABETES (20-79 YEARS) IN 2021, BY COUNTRY
TABLE 2 LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS
5.2.1.1.3 Increasing number of surgical procedures across the globe
5.2.1.1.4 Increasing number of traumatic wounds
TABLE 3 PREVALENCE OF ROAD ACCIDENTS
5.2.1.2 Increasing incidence of burn injuries
5.2.1.3 Innovations in wound care biologics
5.2.2 MARKET RESTRAINTS
5.2.2.1 High cost of wound care biologic products
TABLE 4 AVERAGE COST OF TREATMENT FOR DIABETIC FOOT ULCERS (2018)
5.2.2.2 Risk of skin substitute failure
TABLE 5 COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS)
5.2.3 OPPORTUNITIES
5.2.3.1 Growth potential of emerging economies
TABLE 6 STRATEGIC DEVELOPMENTS IN THE ASIA PACIFIC
5.2.3.2 3D skin printing
5.3 IMPACT OF COVID-19 ON THE WOUND CARE BIOLOGICS MARKET
6 WOUND CARE BIOLOGICS MARKET, BY PRODUCT (Page No. - 57)
6.1 INTRODUCTION
TABLE 7 WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
6.2 BIOLOGICAL SKIN SUBSTITUTES
TABLE 9 KEY PRODUCTS IN THE BIOLOGICAL SKIN SUBSTITUTES MARKET
TABLE 10 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2017-2020 (USD MILLION)
TABLE 11 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2021-2027 (USD MILLION)
TABLE 12 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2017-2020 (USD MILLION)
TABLE 13 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2021-2027 (USD MILLION)
6.2.1 HUMAN DONOR TISSUE-DERIVED PRODUCTS
6.2.1.1 High efficacy of human donor tissue-derived products to support market demand
TABLE 14 KEY PRODUCTS IN THE HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET
TABLE 15 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION, 2017-2020 (USD MILLION)
TABLE 16 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION, 2021-2027 (USD MILLION)
6.2.2 ACELLULAR ANIMAL-DERIVED PRODUCTS
6.2.2.1 Recognition of the importance of ECM in wound treatment has led to the development of acellular wound care biologics
TABLE 17 KEY PRODUCTS IN THE ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET
TABLE 18 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION, 2017-2020 (USD MILLION)
TABLE 19 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION, 2021-2027 (USD MILLION)
6.2.3 BIOSYNTHETIC PRODUCTS
6.2.3.1 Increased bioburden of infected wounds to stimulate market growth
TABLE 20 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2017-2020 (USD MILLION)
TABLE 21 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2021-2027 (USD MILLION)
6.3 TOPICAL AGENTS
6.3.1 INCREASE IN THE NUMBER OF CHRONIC ULCERS OVER THE LAST FEW YEARS TO PROPEL MARKET GROWTH
TABLE 22 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2017-2020 (USD MILLION)
TABLE 23 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2021-2027 (USD MILLION)
7 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE (Page No. - 67)
7.1 INTRODUCTION
TABLE 24 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 25 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
7.1.1 PRIMARY NOTES
7.1.1.1 Key industry insights
7.2 ULCERS
TABLE 26 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION, 2017-2020 (USD MILLION)
TABLE 27 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION, 2021-2027 (USD MILLION)
TABLE 28 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE, 2017-2020 (USD MILLION)
TABLE 29 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE, 2021-2027 (USD MILLION)
7.2.1 DIABETIC FOOT ULCERS
7.2.1.1 Increasing prevalence of diabetes to drive market growth
TABLE 30 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2017-2020 (USD MILLION)
TABLE 31 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2021-2027 (USD MILLION)
7.2.2 VENOUS ULCERS
7.2.2.1 Rising prevalence of obesity to drive market growth
TABLE 32 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2017-2020 (USD MILLION)
TABLE 33 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2021-2027 (USD MILLION)
7.2.3 PRESSURE ULCERS
7.2.3.1 Growing geriatric population to drive market growth
TABLE 34 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2017-2020 (USD MILLION)
TABLE 35 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2021-2027 (USD MILLION)
7.2.4 OTHER ULCERS
TABLE 36 COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS
TABLE 37 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION, 2017-2020 (USD MILLION)
TABLE 38 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION, 2021-2027 (USD MILLION)
7.3 SURGICAL & TRAUMATIC WOUNDS
7.3.1 RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
TABLE 39 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2017-2020 (USD MILLION)
TABLE 40 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2021-2027 (USD MILLION)
7.4 BURNS
7.4.1 HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH
TABLE 41 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION, 2017-2020 (USD MILLION)
TABLE 42 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION, 2021-2027 (USD MILLION)
8 WOUND CARE BIOLOGICS MARKET, BY END USER (Page No. - 80)
8.1 INTRODUCTION
TABLE 43 WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 44 WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
8.2 HOSPITALS
8.2.1 INCREASING NUMBER OF HOSPITALS & HIGH PATIENT INFLOW IN THIS CARE SETTING TO SUPPORT MARKET GROWTH
TABLE 45 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 2017-2020 (USD MILLION)
TABLE 46 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 2021-2027 (USD MILLION)
8.3 AMBULATORY SURGERY CENTERS
8.3.1 GROWING NUMBER OF SURGICAL PROCEDURES PERFORMED IN ASCS WILL ENSURE MARKET GROWTH IN THIS SEGMENT
TABLE 47 NUMBER OF BURN PATIENTS PER 1,000 ASC ADMISSIONS
TABLE 48 PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGERY CENTERS IN THE US
TABLE 49 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017-2020 (USD MILLION)
TABLE 50 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2027 (USD MILLION)
8.4 BURN CARE CENTERS & WOUND CLINICS
8.4.1 RISING GERIATRIC POPULATION AND THE SUBSEQUENT INCREASE IN THE DEMAND FOR ASSISTED LIVING FACILITIES TO SUPPORT MARKET GROWTH
TABLE 51 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2017-2020 (USD MILLION)
TABLE 52 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2021-2027 (USD MILLION)
9 WOUND CARE BIOLOGICS MARKET, BY REGION (Page No. - 87)
9.1 INTRODUCTION
TABLE 53 WOUND CARE BIOLOGICS MARKET, BY REGION, 2017-2020 (USD MILLION)
TABLE 54 WOUND CARE BIOLOGICS MARKET, BY REGION, 2021-2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 19 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT
TABLE 55 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 56 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
TABLE 57 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 58 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 59 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 60 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 61 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 62 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing prevalence of diabetes and non-healing foot ulcers to support the uptake of wound biologics products
TABLE 63 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 64 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 65 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 66 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 67 US: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 68 US: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising geriatric patient pool to drive market growth for wound biologics in Canada
TABLE 69 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
TABLE 70 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 71 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 72 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 73 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 74 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 75 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.3 EUROPE
TABLE 76 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 77 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
TABLE 78 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 79 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 80 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 81 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 82 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 83 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.3.1 UK
9.3.1.1 Increasing incidence of venous ulcers to drive the market growth
TABLE 84 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 85 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 86 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 87 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 88 UK: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 89 UK: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 The large diabetic population in Germany supports the uptake of wound biologics in Germany
TABLE 90 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 91 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 92 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 93 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 94 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 95 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising government support to drive the demand for wound care biologics products in France
TABLE 96 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 97 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 98 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 99 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 100 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 101 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.3.4 REST OF EUROPE
TABLE 102 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 103 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 104 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 105 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 106 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 107 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 20 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET SNAPSHOT
TABLE 108 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
TABLE 109 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2021-2027 (USD MILLION)
TABLE 110 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 111 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 112 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 113 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 114 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 115 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Increasing incidence of DFUs to propel the market growth
TABLE 116 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 117 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 118 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 119 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 120 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 121 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Growing geriatric population to drive the adoption of wound care products
TABLE 122 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 123 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 124 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 125 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 126 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 127 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growing medical tourism in the country to support the market growth for wound biologics
TABLE 128 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 129 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 130 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 131 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 132 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 133 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 134 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 135 ROAPAC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 136 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 137 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 138 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 139 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.5 LATIN AMERICA
9.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE MARKET GROWTH
TABLE 140 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 141 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 142 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 143 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 144 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 145 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 SIGNIFICANT GROWTH IN HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET GROWTH FOR WOUND BIOLOGICS
TABLE 146 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017-2020 (USD MILLION)
TABLE 147 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021-2027 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017-2020 (USD MILLION)
TABLE 149 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021-2027 (USD MILLION)
TABLE 150 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017-2020 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021-2027 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 130)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE WOUND CARE BIOLOGICS MARKET
TABLE 152 OVERVIEW OF STRATEGIES DEPLOYED BY KEY WOUND CARE BIOLOGICS MANUFACTURING COMPANIES
10.3 MARKET SHARE ANALYSIS
10.3.1 WOUND CARE BIOLOGICS MARKET
FIGURE 21 WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 153 WOUND CARE BIOLOGICS MARKET: DEGREE OF COMPETITION
10.4 COMPANY EVALUATION QUADRANT
10.4.1 LIST OF EVALUATED VENDORS
10.4.2 STARS
10.4.3 EMERGING LEADERS
10.4.4 PERVASIVE PLAYERS
10.4.5 PARTICIPANTS
FIGURE 22 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
FIGURE 23 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
10.6 COMPETITIVE SCENARIO
10.6.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 154 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
10.6.2 DEALS
TABLE 155 KEY DEALS
10.6.3 OTHER DEVELOPMENTS
TABLE 156 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 139)
11.1 KEY PLAYERS
(Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats)*
11.1.1 SMITH & NEPHEW PLC
TABLE 157 SMITH & NEPHEW PLC: BUSINESS OVERVIEW
FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021)
11.1.2 ORGANOGENESIS INC.
TABLE 158 ORGANOGENESIS INC.: BUSINESS OVERVIEW
FIGURE 25 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2021)
11.1.3 MIMEDX
TABLE 159 MIMEDX: BUSINESS OVERVIEW
FIGURE 26 MIMEDX: COMPANY SNAPSHOT (2021)
11.1.4 INTEGRA LIFESCIENCES
TABLE 160 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
FIGURE 27 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021)
11.1.5 STRYKER CORPORATION
TABLE 161 STRYKER CORPORATION: BUSINESS OVERVIEW
FIGURE 28 STRYKER CORPORATION: COMPANY SNAPSHOT (2021)
11.1.6 MÖLNLYCKE HEALTH CARE AB
TABLE 162 MÖLNLYCKE HEALTH CARE AB: BUSINESS OVERVIEW
FIGURE 29 MÖLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2021)
11.1.7 VERICEL CORPORATION
TABLE 163 VERICEL CORPORATION: BUSINESS OVERVIEW
FIGURE 30 VERICEL CORPORATION: COMPANY SNAPSHOT (2021)
11.1.8 ANIKA THERAPEUTICS, INC.
TABLE 164 ANIKA THERAPEUTICS, INC.: BUSINESS OVERVIEW
FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2021)
11.1.9 BIOVENTUS LLC
TABLE 165 BIOVENTUS LLC: BUSINESS OVERVIEW
FIGURE 32 BIOVENTUS LLC: COMPANY SNAPSHOT (2021)
11.1.10 ABBVIE INC.
TABLE 166 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2021)
11.1.11 KERECIS
TABLE 167 KERECIS: BUSINESS OVERVIEW
11.1.12 MARINE POLYMER TECHNOLOGIES, INC.
TABLE 168 MARINE POLYMER TECHNOLOGIES, INC.: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 MERAKRIS THERAPEUTICS
TABLE 169 MERAKRIS THERAPEUTICS: COMPANY OVERVIEW
11.2.2 POLYMEDICS INNOVATIONS GMBH
TABLE 170 POLYMEDICS INNOVATIONS GMBH: COMPANY OVERVIEW
11.2.3 FIBROHEAL WOUNDCARE PVT. LTD.
TABLE 171 FIBROHEAL WOUNDCARE PVT. LTD.: COMPANY OVERVIEW
11.2.4 ANAMAY BIOTECH, INC.
TABLE 172 ANAMAY BIOTECH, INC.: COMPANY OVERVIEW
11.2.5 VIRCHOW BIOTECH PRIVATE LIMITED
TABLE 173 VIRCHOW BIOTECH PRIVATE LIMITED: COMPANY OVERVIEW
11.2.6 MEDLINE INDUSTRIES, LP
TABLE 174 MEDLINE INDUSTRIES, LP: COMPANY OVERVIEW
11.2.7 TIDES MEDICAL
TABLE 175 TIDES MEDICAL: COMPANY OVERVIEW
11.2.8 VISCUS BIOLOGICS LLC
TABLE 176 VISCUS BIOLOGICS LLC: COMPANY OVERVIEW
11.2.9 STABILITY BIOLOGICS
TABLE 177 STABILITY BIOLOGICS: COMPANY OVERVIEW
11.2.10 MTF BIOLOGICS
TABLE 178 MTF BIOLOGICS: COMPANY OVERVIEW
11.2.11 SKYE BIOLOGICS HOLDINGS, LLC
TABLE 179 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW
11.2.12 ALLOSOURCE
TABLE 180 ALLOSOURCE: COMPANY OVERVIEW
11.2.13 SURGILOGIX
TABLE 181 SURGILOGIX: COMPANY OVERVIEW
*Details on Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 174)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
